- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00001024
The Effects of Anti-HIV Drugs in HIV-Infected Patients Who Do Not Have AIDS
A Multicenter, Open-Label Study of Viral Burden in Peripheral Blood Versus Lymphoid Tissue Before and After Antiretroviral Therapy in HIV-Infected Individuals Without AIDS (NOTE: One Arm Receives no Treatment)
Immunopathogenesis objectives: To compare and quantitatively determine HIV burden and HIV replication in peripheral blood (PB) and lymphoid tissue (LT). To determine the degree to which antiretroviral therapy alters HIV replication in LT.
Clinical objectives: To gain insight into the degree of correlation between immunologic surrogate markers for HIV disease (e.g., CD4, beta-2 microglobulin) as compared to measures of HIV replication in PB and LT. To assess changes in PB and LT viral burden after antiretroviral therapy and to determine its ability to predict an antiviral response.
One of the major problems in defining the immunopathogenic changes in HIV infections has been the inability to correlate the extent of loss of immunologic function with the number of HIV-infected CD4+ cells in the peripheral blood. Few studies exist that measure viral burden in lymph nodes of HIV-infected individuals. Researchers hope to find out whether the amount of HIV virus or markers for the virus in the body's lymph tissue is a better measure of disease progression than the amount of virus or markers for the virus in the blood.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
One of the major problems in defining the immunopathogenic changes in HIV infections has been the inability to correlate the extent of loss of immunologic function with the number of HIV-infected CD4+ cells in the peripheral blood. Few studies exist that measure viral burden in lymph nodes of HIV-infected individuals. Researchers hope to find out whether the amount of HIV virus or markers for the virus in the body's lymph tissue is a better measure of disease progression than the amount of virus or markers for the virus in the blood.
Sixteen antiretroviral-naive patients are randomized to either remain antiretroviral-naive (no treatment) or receive zidovudine daily (treatment). Additionally, 16 patients with 26 or more weeks of ongoing zidovudine (AZT) therapy are randomized to either continue on their prestudy AZT regimen or add didanosine (ddI) daily to their baseline AZT dose. Patients remain on their assigned treatment arms for 8 weeks. A lymph node biopsy is performed on day 0 and at week 8. Patients are evaluated at weeks 2, 4, 6, 8 and 9.
Undersøgelsestype
Tilmelding
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
California
-
Palo Alto, California, Forenede Stater, 94304
- Palo Alto Veterans Affairs Health Care System
-
San Francisco, California, Forenede Stater, 94115
- Kaiser Permanente Med Ctr
-
San Francisco, California, Forenede Stater, 94115
- Mount Zion Med Ctr / UCSF
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60612
- Univ of Illinois
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21201
- Univ of Maryland at Baltimore
-
-
New York
-
Stony Brook, New York, Forenede Stater, 117948153
- SUNY / Health Sciences Ctr at Stony Brook
-
-
North Carolina
-
Durham, North Carolina, Forenede Stater, 27710
- Duke Univ Med Ctr
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forenede Stater, 15261
- Univ of Pittsburgh
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria
Concurrent Medication:
Allowed:
- Chemoprophylaxis against M. tuberculosis, therapy for oral candidiasis, and short courses (up to 10 days) of acyclovir for herpes lesions.
- Antibiotics as clinically indicated.
- Pneumococcal vaccine and hepatitis B vaccine as medically indicated.
- Regularly prescribed medications such as antipyretics, analgesics, allergy medications, antidepressants, sleep medications, oral contraceptives, or other medications deemed appropriate by the patient's primary care provider.
Recommended:
- PCP prophylaxis if patient's CD4 count falls below 200 cells/mm3 during the study.
Concurrent Treatment:
Allowed:
- Alternative therapies such as vitamins and acupuncture.
Patients must have:
- Documented HIV infection.
- At least two palpable lymph nodes above the waist.
- CD4 counts >= 350 cells/mm3 (if previously antiretroviral-naive) or >= 250 cells/mm3 (if receiving ongoing AZT therapy).
Patients with prior AZT therapy must have received a stable dose of 300-600 mg daily for 26 or more weeks.
Prior Medication:
Required in patients with prior ongoing therapy:
- AZT at dose of 300-600 mg daily for at least 26 weeks.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms and conditions are excluded:
- Severe malabsorption.
- Current AIDS-related opportunistic infection, AIDS dementia, AIDS-wasting syndrome, or an AIDS-related malignancy other than minimal Kaposi's sarcoma disease.
- Current medical problems that may interfere with the evaluation of AZT or increase the potential toxicity of AZT (e.g., significant liver disease, diabetes, significant cardiovascular disease, seizure disorders, lymphoma, acute or chronic pancreatitis, or febrile illness).
- Current diagnosis of malignancy for which systemic therapy would be required during study.
Concurrent Medication:
Excluded:
- Ganciclovir, foscarnet, chronic acyclovir, or probenecid.
- Other proven or alleged antiretroviral or anti-HIV drugs.
- Biologic response modifiers.
- Valproic acid.
- Systemic cytotoxic chemotherapy.
- Steroids.
Concurrent Treatment:
Excluded:
- Radiation therapy.
Patients with the following prior conditions are excluded:
- Prior AIDS-related opportunistic infection, AIDS dementia, AIDS-wasting syndrome, or an AIDS-related malignancy other than minimal Kaposi's sarcoma disease.
- History of medical problems that may interfere with the evaluation of AZT or increase the potential toxicity of AZT (e.g., significant liver disease, diabetes, significant cardiovascular disease, seizure disorders, lymphoma, acute or chronic pancreatitis, or febrile illness).
- History of peripheral neuropathy (patients with prior AZT treatment only).
Prior Medication:
Excluded:
- Prior ddI therapy.
- Less than 26 weeks of prior AZT (in patients with ongoing AZT therapy only).
- Ganciclovir, foscarnet, chronic acyclovir, or probenecid.
- Cytotoxic chemotherapy within 1 month prior to study entry.
- Acute therapy for an infection or other medical illness within 14 days prior to study entry.
History of alcohol abuse (patients with prior AZT treatment).
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
Samarbejdspartnere og efterforskere
Efterforskere
- Studiestol: M Niu
- Studiestol: J Cohn
Publikationer og nyttige links
Generelle publikationer
- Cohen OJ, Pantaleo G, Graziosi C, Niu M, Fauci AS. Effect of antiretroviral therapy on HIV burden and replication in lymphoid tissue. DATRI 003 Study Group. Int Conf AIDS. 1994 Aug 7-12;10(1):7 (abstract no 001B)
Datoer for undersøgelser
Studer store datoer
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- RNA-virusinfektioner
- Virussygdomme
- Infektioner
- Blodbårne infektioner
- Overførbare sygdomme
- Seksuelt overførte sygdomme, virale
- Seksuelt overførte sygdomme
- Lentivirus infektioner
- Retroviridae infektioner
- Immunologiske mangelsyndromer
- Sygdomme i immunsystemet
- HIV-infektioner
- Molekylære mekanismer for farmakologisk virkning
- Anti-infektionsmidler
- Antivirale midler
- Reverse transkriptasehæmmere
- Nukleinsyresyntesehæmmere
- Enzymhæmmere
- Anti-HIV-midler
- Anti-retrovirale midler
- Antimetabolitter
- Zidovudin
- Didanosin
Andre undersøgelses-id-numre
- DATRI 003
- 11734 (Registry Identifier: DAIDS ES Registry Number)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med HIV-infektioner
-
University of Santiago de CompostelaOsteology FoundationRekruttering
-
Institut PasteurRekruttering
-
Universidad del DesarrolloAfsluttetHealthcare Associated InfectionChile
-
The University of Texas Health Science Center,...EurofinsAfsluttetOdontogen Deep Space Neck InfectionForenede Stater
-
Imelda Hospital, BonheidenAfsluttetHealthcare Associated InfectionBelgien
-
University of PennsylvaniaAfsluttetAntimikrobiel resistensForenede Stater, Botswana
-
University of Maryland, BaltimoreVA Office of Research and DevelopmentAfsluttetMenneskelig mikrobiomForenede Stater
-
Universidad Autonoma de Nuevo LeonUkendtSundhedsrelaterede infektioner
-
Centre Hospitalier Universitaire de NīmesRekrutteringÆldre | Healthcare Associated InfectionFrankrig
-
Centre Hospitalier Universitaire, AmiensAfsluttetHealthcare Associated Infection | IglerFrankrig
Kliniske forsøg med Zidovudin
-
Glaxo WellcomeUkendtHIV-infektionerForenede Stater
-
Glaxo WellcomeAfsluttet
-
Institut de Recherche pour le DeveloppementEunice Kennedy Shriver National Institute of Child Health and Human Development... og andre samarbejdspartnereAfsluttetHIV-infektioner | GraviditetThailand
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...AfsluttetHIV-infektionerForenede Stater, Puerto Rico
-
Glaxo WellcomeAfsluttetHIV-infektioner | LipodystrofiForenede Stater
-
Glaxo WellcomeAfsluttet
-
ViiV HealthcareAfsluttet
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...AfsluttetHIV-infektionerForenede Stater, Puerto Rico
-
University of Colorado, DenverNational Institute of Allergy and Infectious Diseases (NIAID); University...Afsluttet
-
Agouron PharmaceuticalsSuspenderetHIV-infektionerForenede Stater, Canada, Puerto Rico, Dominikanske republik